Companies · RPRX
Royalty Pharma
AI-generated · informational only · not investment advice · verify before relying.
Latest analysis
Updated Nov 4, 2026
Royalty Pharma raises full-year 2026 guidance for the third consecutive quarter as Portfolio Receipts grow 9% and development pipeline posts 90% Phase III success rate
Royalty Pharma delivered 9% Portfolio Receipts growth in Q3 2026 and 12% Royalty Receipts growth year-to-date, driven by Tremfya, Voranigo, Evrysdi, and Imdelltra, while absorbing a combined ~5% headwind from Promacta and Imbruvica declines. Management raised full-year 2026 Portfolio Receipts guidance to $3.5–$3.55 billion — the third consecutive upward revision — and reaffirmed its $4.7 billion 2030 top-line target. Two new royalty acquisitions (Mimrylo and Zoryve, $100 million each) and a $1 billion R&D co-funding deployment year-to-date demonstrate accelerating capital deployment across both approved products and development-stage assets.
Tone: bullishRevenue
$2.4B
RPRX 10-K · FY 2025
Employees
100
Revenue FY2024
$2.3B
Founded
1996
Profile
RPRX 10-K Item 1 · Feb 11, 2026Royalty Pharma is the largest buyer of biopharmaceutical royalties, acquiring contractual rights to payments based on top-line sales of approved and development-stage therapies across oncology, rare disease, immunology, neuroscience and other areas. The company operates without fixed R&D, manufacturing or commercial infrastructure, instead deploying capital to acquire royalties from academic institutions, biotechnology companies and large pharmaceutical firms. Its portfolio spans more than 35 marketed products and 20 development-stage candidates.
Read filing description ↓ Collapse description ↑
We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. Since our founding in 1996, we have been pioneers in the royalty market, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. We have assembled a portfolio of royalties which entitles us to payments based directly on the top-line sales of many of the industry's leading therapies, which includes royalties on more than 35 commercial products, including Vertex's Trikafta and Alyftrek, GSK's Trelegy, Biogen's Tysabri and Spinraza, Roche's Evrysdi, Astellas and Pfizer's Xtandi, Johnson & Johnson's Tremfya, AbbVie and Johnson & Johnson's Imbruvica, Servier's Voranigo, Gilead's Trodelvy, Amgen's Imdelltra and Alnylam's Amvuttra, among others, and 20 development-stage product candidates. We strive to be the premier capital allocator in life sciences with consistent, compounding growth. Our highly selective investment approach focuses on identifying and tracking important new therapies, which allows us to act efficiently when opportunities arise. Our model combines a unique structure, long investment time horizon, structuring flexibility, scale and diversification, and singular focus on biopharmaceuticals. This is reinforced by our investment platform anchored in deep life sciences expertise, exceptional talent, extensive industry relationships, an industrialized investment process and proprietary data and analytics capabilities.
Primary products
- Third-party Royalties
- Synthetic Royalties
- Other Funding Modalities
End markets
Geographies
Named customers
In 2025, no individual product accounted for more than 26% of our Portfolio Receipts.
“We have executed transactions with an aggregate announced value of $19.4 billion from 2020 through 2025, which represents an estimated market share of approximately 48% of all royalty transactions during this period.” Competitive position, as stated in the filing
Revenue commentary · FY 2025
Total income and other revenues increased from approximately $2.26 billion in 2024 to approximately $2.38 billion in 2025, driven by growth in income from financial royalty assets.
The rest of RPRX is for subscribers
Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.